When was Angitia founded?

Angitia was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Angitia located?

Angitia is headquartered in Woodland Hills, United States.

Who is the current CEO of Angitia?

Hua Zhu Ke of Angitia. They have also founded 1 company.

How many employees does Angitia have?

As of Jun 30, 2026, the latest employee count at Angitia is 62.

Is Angitia a funded company?

Angitia is a funded company, having raised a total of $406M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 18, 2020.

How much is Angitia worth?

The latest valuation of Angitia is $***** as of Feb 05, 2026.

When was the latest funding round of Angitia?

Angitia's latest funding was a $***** Series D round on Feb 05, 2026, with participation from 18 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $741M in funding in 2026 to date.

Where does Angitia rank among its competitors?

Angitia ranks 12th amongst 155 active competitors, of which 39 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Quince Therapeutics, which secured $187M in May, 2026.

Who are the top competitors of Angitia?

Angitia's top competitors include Biogen, argenx and AskBio. Among them, Quince Therapeutics secured the most recent funding round in May, 2026.

Angitia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for muscle, bone, and joint diseases. The company's products include AGAO1 for bone fusion, AGA02 for rare diseases, AGA03 for regeneration, AGA04 for osteoporosis, AGA05 for healing, and others. Also, developed many drugs for multiple disease treatments such as nonunion of fractures, osteoarthritis, rare diseases of skeletal muscle, and mineral metabolism diseases caused by diseases or disorders of endocrine organs.

Website: www.angitiabio.com
Email ID: *****@angitiabio.com
Phone Number: +86 **********
Part Of

Key Metrics

Founded Year

2018

Location

Woodland Hills, United States

Stage

Series D

Total Funding

$406M in 6 rounds

Latest Funding Round

Series D, Feb 05, 2026, $*****

Post Money Valuation

$***** as on Feb 05, 2026

Investors

Venrock & 29 more

Ranked

12^th among 155 active competitors

Employee Count

62 as on Jun 30, 2026

Similar Companies

argenx & 135 more

View Angitia's full profile

Angitia has raised a total funding of $406M over 6 rounds. Its first funding round was on Aug 18, 2020. Its latest funding round was a Series D round on Feb 05, 2026 for $*****. 18 investors participated in its latest round. Angitia has 30 institutional investors.

Here is the list of recent funding rounds of Angitia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 05, 2026	1810811	Series D	3701354	8573672	9160742	5412535
Dec 11, 2024	8771111	Series C	2481468	6382361	7720323	Orbimed & 4 more
Jan 2024	6221128	Series B	8005920	2073496	Guangzhou Hi-Tech Communication Technology	Guangdong Capital

Access funding benchmarks and valuations. Sign up today!

View details of Angitia's funding rounds and investors

The founders of Angitia is Hua Zhu Ke. Hua Zhu Ke is the CEO of Angitia.

Here are the details of Angitia's key team members:

Hua Zhu Ke: Co-Founder & CEO of Angitia.

View details of Angitia's Founder profiles and Board Members

Angitia's employee count trend

Angitia has 62 employees as of Jun 26. Here is Angitia's employee count trend over the years:

Uncover Angitia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Angitia include Biogen, argenx and AskBio. Here is the list of Top 10 competitors of Angitia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
3rd	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
4th	Cytokinetics 1997, San Francisco (United States), Public	Developer of muscle activators as potential treatments for debilitating diseases	$60M	Vulcanventuresinvestments.com, Foresite Capital ... & 12 others	68/100
5th	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
6th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
7th	Radius Health 2003, Boston (United States), Acquired	Biopharmaceutical company focused on bone health and related therapeutic areas	$213M	MPM BioImpact, Wellcome & 14 others	63/100
8th	BioAge Labs Emeryville (United States), Public	Provider of a bioinformatics platform for biomarkers and drug discovery	$294M	Andreessen Horowitz, Sofinnova Investments ... & 27 others	62/100
9th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	Atlas Venture, Avoro Capital & 4 others	61/100
10th	Quince Therapeutics 2012, San Francisco (United States), Public	Developer of therapeutics for orthopedic diseases	$108M	Pfizer Venture Investments, Balyasny Asset Management ... & 26 others	60/100
12th	Angitia 2018, Woodland Hills (United States), Series D	Developer of drugs for muscle, bone, and joint diseases	$406M	Bain Capital Life Sciences, BVF Partners ... & 28 others	58/100